Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBluejay Diagnostics Inc

Bluejay Diagnostics Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
2.8 USD -0.01 ( 0.36%)
Last update at 2026-11-11T21:00:00Z
VOLUME
16474
Market Cap
2.04M

Momentum Score

…

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.61
Low
2.80
High
52 Week Price Range
1.65
Low
16.68
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bluejay Diagnostics Inc is a Nasdaq-listed company that, per public filings, develops molecular and point-of-care diagnostic tests for respiratory infections. Long-term growth drivers may include wider adoption of rapid respiratory diagnostics, regulatory clearances, commercialization partnerships and recurring consumable sales to support scale. Investors may find exposure to diagnostic test demand and potential recurring revenue attractive for a longer-term outlook.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.81
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.05M
Debt / Equity
0.02
ROE
-117.02%
Net Debt
-5.04M
ROCE
-114.13%
Diluted EPS TTM
-15.25

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.85M -7.72M -9.95M -9.30M -3.49M
Net income -6.85M -7.72M -9.95M -9.23M -3.73M
Selling general administrative 3.91M 3.69M 4.31M 4.76M 1.79M
Selling and marketing expenses - 0.01M 0.28M 0.45M 0.29M
Gross profit -0.17M -0.20M -0.78M 0.05M -
Reconciled depreciation 0.17M 0.20M 0.79M 0.31M 0.15M
Ebit -6.85M -6.89M -9.95M -9.32M -3.23M
Ebitda -6.68M -6.70M -9.17M -9.06M -3.14M
Depreciation and amortization 0.17M 0.20M 0.78M 0.26M 0.09M
Operating income -6.95M -7.17M -10.31M -9.32M -3.23M
Other operating expenses 6.95M 7.17M 10.31M 9.57M 3.16M
Interest expense 0.00M 0.82M 0.00M -0.02M 0.37M
Interest income 0.10M 0.15M 0.16M - -
Net interest income 0.10M -0.68M 0.16M 0.00M -0.37M
Income tax expense - - 0.00M -0.07M 0.24M
Total revenue 0.00M 0.00M 0.00M 0.25M 0.00M
Total operating expenses 6.95M 7.17M 10.31M 9.37M 3.16M
Cost of revenue 0.17M 0.20M 0.78M 0.20M -
Total other income expense net 0.10M -0.55M 0.36M 0.02M -0.26M
Net income from continuing ops -6.85M -7.72M -10.04M -9.30M -3.49M
Net income applicable to common shares - - - -9.30M -3.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.12M 6.66M 4.87M 13.52M 21.02M
Intangible assets - - - 0.00M 0.00M
Other current assets 0.30M 0.58M 0.71M 1.67M 1.61M
Total liab 1.14M 0.93M 1.97M 1.98M 0.64M
Total stockholder equity 5.98M 5.73M 2.89M 11.54M 20.38M
Other current liab 0.80M 0.55M 1.11M 0.84M 0.34M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -41.52M -34.67M -26.95M -17.00M -7.69M
Other assets - - 0.00M 0.04M 0.02M
Cash 5.16M 4.30M 2.21M 10.11M 19.05M
Total current liabilities 1.12M 0.81M 1.77M 1.64M 0.64M
Net debt -5.04M -4.08M -1.84M -9.62M -19.05M
Short term debt 0.10M 0.11M 0.17M 0.17M -
Short long term debt total 0.12M 0.22M 0.37M 0.49M -
Other stockholder equity 47.49M 40.40M 29.85M 28.54M 28.07M
Property plant equipment - - - 1.70M 0.34M
Total current assets 5.46M 4.90M 2.96M 11.79M 20.66M
Net tangible assets - - - 11.54M 20.38M
Net receivables - 0.01M 0.04M - -
Inventory - - - - 0.00M
Accounts payable 0.21M 0.15M 0.49M 0.64M 0.30M
Accumulated other comprehensive income - - - - -21.02M
Non currrent assets other 0.01M 0.04M 0.29M 0.03M 0.02M
Non current assets total 1.66M 1.76M 1.91M 1.73M 0.36M
Capital lease obligations 0.12M 0.22M 0.35M 0.51M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.31M -0.85M -1.20M -0.02M
Change to liabilities - - - 0.30M -0.08M
Total cashflows from investing activities -0.17M -0.31M -0.70M -1.20M -0.02M
Net borrowings -0.00M -0.00M -0.00M -0.00M 4.20M
Total cash from financing activities 7.09M 10.22M 1.11M 0.01M 22.53M
Change to operating activities - - - 0.28M -1.49M
Net income -6.85M -7.72M -9.95M -9.30M -3.49M
Change in cash 0.86M 2.09M -7.91M -8.93M 18.14M
Begin period cash flow 4.30M 2.21M 10.11M 19.05M 0.91M
End period cash flow 5.16M 4.30M 2.21M 10.11M 19.05M
Total cash from operating activities -6.05M -7.82M -8.31M -7.74M -4.37M
Issuance of capital stock 8.35M 12.07M 1.59M 0.00M 18.86M
Depreciation 0.17M 0.20M 0.78M 0.31M 0.15M
Dividends paid - - - - -0.02M
Change to inventory - - - 0.00M 0.08M
Change to account receivables - - - - 0.00M
Sale purchase of stock - - -0.06M - 0.02M
Other cashflows from financing activities 7.09M -1.84M 0.96M -0.02M 3.97M
Change to netincome - - - 0.67M 0.46M
Capital expenditures 0.17M 0.31M 0.70M 1.20M 0.02M
Change in working capital 0.58M -0.63M 0.67M 0.58M -1.49M
Stock based compensation 0.00M 0.02M 0.19M 0.43M 0.07M
Other non cash items 0.04M 0.31M 0.00M 0.24M 0.22M
Free cash flow -6.23M -8.13M -9.02M -8.94M -4.39M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BJDX
Bluejay Diagnostics Inc		 -0.01
0.36%		 2.80 - - 54.99 0.34 5.67 -0.10
ABT
Abbott Laboratories		 -1.17
1.06%		 109.29 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.02
0.02%		 101.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -5.50
1.70%		 318.79 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.30
0.63%		 48.57 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Bluejay Diagnostics Inc

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

360 Massachusetts Avenue, Acton, MA, United States, 01720

844 327 7078

https://bluejaydx.com

6

Name Title Year Born
Mr. Indranil Dey Pres, CEO & Director 1964
Dr. Jason Cook Chief Technology Officer 1982
Mr. Kenneth R. Fisher CPA Chief Financial Officer 1980
Mr. Kevin Vance Chief Commercial Officer 1957
Mark W. Feinberg Chief Medical Advisor NA
Dr. Mark W. Feinberg M.D. Chief Medical Advisor NA
Mr. Indranil Dey Principal Financial, Accounting & Executive Officer, President, CEO and Director 1964
Dr. Jason Cook Chief Technology Officer 1983
Mr. Les DeLuca Vice President of Operations NA
Eryn Graham Marketing Manager NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…